This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krosky, P. M.
Right arrow Articles by Coen, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krosky, P. M.
Right arrow Articles by Coen, D. M.

 Previous Article  |  Next Article 

Journal of Virology, January 2003, p. 905-914, Vol. 77, No. 2
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.2.905-914.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

The Human Cytomegalovirus UL97 Protein Kinase, an Antiviral Drug Target, Is Required at the Stage of Nuclear Egress{dagger}

Paula M. Krosky,{ddagger} Moon-Chang Baek,§ and Donald M. Coen*

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115

Received 1 July 2002/ Accepted 9 October 2002

Human cytomegalovirus encodes an unusual protein kinase, UL97, that activates the established antiviral drug ganciclovir and is specifically inhibited by a new antiviral drug, maribavir. We used maribavir and a UL97 null mutant, which is severely deficient in viral replication, to determine what stage of virus infection critically requires UL97. Compared with wild-type virus, there was little or no decrease in immediate-early gene expression, viral DNA synthesis, late gene expression, or packaging of viral DNA into nuclease-resistant structures in mutant-infected or maribavir-treated cells under conditions where the virus yield was severely impaired. Electron microscopy studies revealed similar proportions of various capsid forms, including DNA-containing capsids, in the nuclei of wild-type- and mutant-infected cells. However, capsids were rare in the cytoplasm of mutant-infected or maribavir-treated cells; the magnitudes of these decreases in cytoplasmic capsids were similar to those for virus yield. Thus, genetic and pharmacological evidence indicates that UL97 is required at the stage of infection when nucleocapsids exit from the nucleus (nuclear egress), and this poorly understood stage of virus infection can be targeted by antiviral drugs. Understanding UL97 function and maribavir action should help elucidate this interesting biological process and help identify new antiviral drug targets for an important pathogen in immunocompromised patients.

* Corresponding author. Mailing address: Dept. of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 250 Longwood Ave., Boston, MA 02115. Phone: (617) 432-1691. Fax: (617) 432-3833. E-mail: Don_Coen{at}hms.harvard.edu.

{dagger} We dedicate this paper to the memory of Bill Burns, a valued colleague and friend, who dedicated himself to treating disease and understanding biology.

{ddagger} Present address: Screening Technologies Branch, Developmental Therapeutics Program, NCI Frederick, Frederick, MD 21702.

§ Present address: Division of Molecular and Life Sciences, Pohong University of Science and Technology, Pohong 790-784, Korea.

Journal of Virology, January 2003, p. 905-914, Vol. 77, No. 2
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.2.905-914.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Asai, R., Kato, A., Kato, K., Kanamori-Koyama, M., Sugimoto, K., Sairenji, T., Nishiyama, Y., Kawaguchi, Y. (2006). Epstein-Barr Virus Protein Kinase BGLF4 Is a Virion Tegument Protein That Dissociates from Virions in a Phosphorylation-Dependent Process and Phosphorylates the Viral Immediate-Early Protein BZLF1. J. Virol. 80: 5125-5134 [Abstract] [Full Text]  
  • Ma, J. D., Nafziger, A. N., Villano, S. A., Gaedigk, A., Bertino, J. S. Jr. (2006). Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults. Antimicrob. Agents Chemother. 50: 1130-1135 [Abstract] [Full Text]  
  • Prichard, M. N., Britt, W. J., Daily, S. L., Hartline, C. B., Kern, E. R. (2005). Human Cytomegalovirus UL97 Kinase Is Required for the Normal Intranuclear Distribution of pp65 and Virion Morphogenesis. J. Virol. 79: 15494-15502 [Abstract] [Full Text]  
  • Pesola, J. M., Zhu, J., Knipe, D. M., Coen, D. M. (2005). Herpes Simplex Virus 1 Immediate-Early and Early Gene Expression during Reactivation from Latency under Conditions That Prevent Infectious Virus Production. J. Virol. 79: 14516-14525 [Abstract] [Full Text]  
  • Chou, S., Marousek, G. I., Senters, A. E., Davis, M. G., Biron, K. K. (2004). Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir. J. Virol. 78: 7124-7130 [Abstract] [Full Text]  
  • Nixon, D. E., McVoy, M. A. (2004). Dramatic Effects of 2-Bromo-5,6-Dichloro-1-{beta}-D-Ribofuranosyl Benzimidazole Riboside on the Genome Structure, Packaging, and Egress of Guinea Pig Cytomegalovirus. J. Virol. 78: 1623-1635 [Abstract] [Full Text]  
  • Jones, T. R., Lee, S.-W. (2004). An Acidic Cluster of Human Cytomegalovirus UL99 Tegument Protein Is Required for Trafficking and Function. J. Virol. 78: 1488-1502 [Abstract] [Full Text]  
  • Komazin, G., Ptak, R. G., Emmer, B. T., Townsend, L. B., Drach, J. C. (2003). Resistance of Human Cytomegalovirus to the Benzimidazole L-Ribonucleoside Maribavir Maps to UL27. J. Virol. 77: 11499-11506 [Abstract] [Full Text]  
  • De Clercq, E. (2003). New inhibitors of human cytomegalovirus (HCMV) on the horizon. J Antimicrob Chemother 51: 1079-1083 [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»